![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
Posts
One of the world's largest #breastcancer tissue banks is being used to study how tumors evolve. What drives an incurable late recurrence many years after the initial diagnosis? ECOG-ACRIN @SWOG & @carisls aim to find out. #EA1241 #bcsm #TAILORx #RxPONDER
TAILORx and RxPONDER trials shift to a discovery platform for analyzing breast cancer recurrence...
Read more about these trials as they leverage one of the world’s largest clinically annotated breast cancer specim...
bit.ly
#ClinicalTrialsDayMN
Don’t miss this @urotoday #AUA26 preview with @PGrivasMDPhD + @UroDocAsh: consolidation after deep response, biomarkers (ctDNA), and bladder preservation—plus a spotlight on the newly launched EA8231 trial. More: https://bit.ly/4dRVbVu #BladderCancer
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
34
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
